Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425579 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02425579 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 12 participants.
The verdict
NCT02425579, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of inhaled carbon monoxide (iCO) in intubated patients with sepsis-induced ARDS.
Interventions
- DRUG Inhaled Carbon Monoxide at 100ppm (4 participants)
- DRUG Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)
- DRUG Inhaled Carbon Monoxide at 200ppm (4 participants)
- DRUG Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02425579
The ClinicalTrials.gov registry entry for NCT02425579 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Inhaled Carbon Monoxide at 100ppm (4 participants) is the first listed.
NCT02425579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02425579 about?
NCT02425579 is a clinical study titled "Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)". The purpose of this study is to assess the safety of inhaled carbon monoxide (iCO) in intubated patients with sepsis-induced ARDS.
What is the current status of trial NCT02425579?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-04. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02425579?
The interventions under investigation include: Inhaled Carbon Monoxide at 100ppm (4 participants) (DRUG), Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants) (DRUG), Inhaled Carbon Monoxide at 200ppm (4 participants) (DRUG), Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants) (DRUG).
Who is sponsoring clinical trial NCT02425579?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.